Fitlife Brands, Inc. splits its revenue 2 ways in its filings. By operating segments, the largest line in fiscal 2025, which ended Dec 31, 2025 was Legacy Fit Life at $62.0 million, 76% of the total. By sales mix, the largest line in fiscal 2025, which ended Dec 31, 2025 was Legacy Fit Life at $62.0 million, 76% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
36
|
81
|
64
|
53
|
29
|
28
|
22
|
19
|
17
|
18
|
25
|
| Operating segments | |||||||||||
| Legacy Fit Life |
—
|
62
-3.8%
share 76.1%
|
64
+129.6%
share 100.0%
|
28
share 53.3%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Irwin |
—
|
19
share 23.9%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Sales mix | |||||||||||
| Legacy Fit Life |
—
|
62
-3.8%
share 76.1%
|
64
+129.6%
share 100.0%
|
28
share 53.3%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Irwin |
—
|
19
share 23.9%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- FTLF (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Omaha, NE
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1374328
- Former names
- BOND LABORATORIES, INC. (until Oct 1, 2013)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.